title: Selective indole-based ECE inhibitors: synthesis and pharmacological evaluation.
abstract: Inhibition of the metalloprotease ECE-1 may be beneficial for the treatment of coronary heart disease, cancer, renal failure, and urological disorders. A novel class of indole-based ECE inhibitors was identified by high throughput screening. Optimization of the original screening lead structure 6 led to highly potent inhibitors such as 11, which bears a bisaryl amide moiety linked to the indole C2 position through an amide group. Docking of 11 into a model structure of ECE revealed a unique binding mode in which the Zn center of the enzyme is not directly addressed by the inhibitor, but key interactions are suggested for the central amide group. Testing of the lead compound 6 in hypertensive Dahl S rats resulted in a decrease in blood pressure after an initial period in which the blood pressure remained unchanged, most probably the result of ET-1 already present. Indole derivative 6 also displays a cardio-protective effect in a mouse model of acute myocardial infarction after oral administration. The more potent chloropyridine derivative 9 antagonizes big-ET-1-induced increase in blood pressure in rats at intravenous administration of 3 mg kg-1. All ECE inhibitors of the indole class showed high selectivity for ECE over related metalloproteases such as NEP and ACE. Therefore, these compounds might have further potential as drugs for the treatment of coronary heart diseases.
authors.affiliation: Bayer HealthCare AG, Business Group Pharma, Research & Development, Aprather Weg 18a, 42096 Wuppertal, Germany.
authors.forename: Michael
authors.initials: M
authors.lastname: Brands
authors.forename: Jens-Kerim
authors.initials: JK
authors.lastname: Ergüden
authors.forename: Kentaro
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Dirk
authors.initials: D
authors.lastname: Heimbach
authors.forename: Thomas
authors.initials: T
authors.lastname: Krahn
authors.forename: Christian
authors.initials: C
authors.lastname: Schröder
authors.forename: Stephan
authors.initials: S
authors.lastname: Siegel
authors.forename: Johannes-Peter
authors.initials: JP
authors.lastname: Stasch
authors.forename: Hideki
authors.initials: H
authors.lastname: Tsujishita
authors.forename: Stefan
authors.initials: S
authors.lastname: Weigand
authors.forename: Nagahiro H
authors.initials: NH
authors.lastname: Yoshida
mesh_terms: D016282:Aspartic Acid Endopeptidases / Q000037:antagonists & inhibitors*; D002853:Chromatography, Liquid; D000072396:Endothelin-Converting Enzymes; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000493:pharmacokinetics / Q000494:pharmacology*; D007211:Indoles / Q000737:chemistry* / Q000493:pharmacokinetics / Q000494:pharmacology*; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D008666:Metalloendopeptidases / Q000037:antagonists & inhibitors*; D008958:Models, Molecular; D015394:Molecular Structure; D013329:Structure-Activity Relationship
chemical_list: D004791:Enzyme Inhibitors; D007211:Indoles; D016282:Aspartic Acid Endopeptidases; D008666:Metalloendopeptidases; C000606925:Ece1 protein, mouse; D000072396:Endothelin-Converting Enzymes